These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 37039036)

  • 1. Breaking the mold: asciminib as a standard-of-care of the therapeutic armamentarium of chronic myeloid leukemia in the upfront setting.
    Yılmaz R; Eşkazan AE
    Future Oncol; 2023 Mar; 19(8):545-547. PubMed ID: 37039036
    [No Abstract]   [Full Text] [Related]  

  • 2. Asciminib as a new option in the treatment of chronic myeloid leukemia.
    İbiş B; Tiribelli M; Eşkazan AE
    Future Oncol; 2021 Dec; 17(36):5003-5005. PubMed ID: 34791894
    [No Abstract]   [Full Text] [Related]  

  • 3. Asciminib: the next-generation bullet for first-line treatment of chronic myeloid leukemia.
    Yoshida C; Takaku T
    Med; 2024 Aug; 5(8):856-858. PubMed ID: 39127034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial.
    Cortes JE; Hochhaus A; Takahashi N; Larson RA; Issa GC; Bombaci F; Ramscar N; Ifrah S; Hughes TP
    Future Oncol; 2022 Dec; 18(38):4161-4170. PubMed ID: 36524980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overcoming TKI resistance in a patient with chronic myeloid leukemia using combination BCR-ABL inhibition with asciminib and bosutinib.
    Hall KH; Brooks A; Waller EK
    Am J Hematol; 2021 Aug; 96(8):E293-E295. PubMed ID: 33971041
    [No Abstract]   [Full Text] [Related]  

  • 7. Asciminib as a third line option in chronic myeloid leukemia.
    Laganà A; Scalzulli E; Carmosino I; Martelli M; Breccia M
    Int J Hematol; 2023 Jan; 117(1):16-23. PubMed ID: 35930119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Asciminib in chronic myeloid leukemia: many questions still remain to be answered.
    Eşkazan AE
    Blood Cancer J; 2021 Apr; 11(4):81. PubMed ID: 33927187
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice.
    Garcia-Gutiérrez V; Luna A; Alonso-Dominguez JM; Estrada N; Boque C; Xicoy B; Giraldo P; Angona A; Alvarez-Larrán A; Sanchez-Guijo F; Ramírez MJ; Mora E; Vélez P; Rosell A; Colorado Araujo M; Cuevas B; Sagüés M; Cortes M; Encinas MP; Casado Montero LF; Moreno Vega M; Serrano L; Gomez V; Garcia-Hernandez C; Lakhwani S; Paz Coll A; de Paz R; Suarez-Varela S; Fernandez-Ruiz A; Perez Lopez R; Ortiz-Fernández A; Jiménez-Velasco A; Steegmann-Olmedillas JL; Hernández-Boluda JC
    Blood Cancer J; 2021 Feb; 11(2):16. PubMed ID: 33563899
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical outcomes of chronic myeloid leukaemia patients taking asciminib through a Managed Access Programme (MAP) in Australia.
    Chee L; Lee N; Grigg A; Chen M; Schwarer A; Szer J; Ratnasingam S; Raj S; Lukito P; Yeung D; Hughes T; Shanmuganathan N
    Intern Med J; 2024 Jul; 54(7):1214-1218. PubMed ID: 38884158
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BCR::ABL1 kinase N-lobe mutants confer moderate to high degrees of resistance to asciminib.
    Leyte-Vidal A; Garrido Ruiz D; DeFilippis R; Leske IB; Rea D; Phan S; Miller KB; Hu F; Mase A; Shan Y; Hantschel O; Jacobson MP; Shah NP
    Blood; 2024 Aug; 144(6):639-645. PubMed ID: 38643492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib: a new therapeutic option in chronic-phase CML with treatment failure.
    Yeung DT; Shanmuganathan N; Hughes TP
    Blood; 2022 Jun; 139(24):3474-3479. PubMed ID: 35468180
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asciminib (Scemblix) for chronic myeloid leukemia.
    Med Lett Drugs Ther; 2023 Jun; 65(1678):e107-e108. PubMed ID: 37339100
    [No Abstract]   [Full Text] [Related]  

  • 14. High Efficacy and Safety of Asciminib in a Chronic Myeloid Leukemia Patient with Chronic Kidney Disease Following Renal Transplantation.
    Uchida Y; Koyama D; Manabe K; Suzuki K; Asano N; Endo M; Fukatsu M; Sano T; Hayashi K; Takano M; Takahashi H; Kimura S; Ikezoe T
    Intern Med; 2024 Mar; 63(5):717-720. PubMed ID: 37407456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel therapeutic approaches in chronic myeloid leukemia.
    Özgür Yurttaş N; Eşkazan AE
    Leuk Res; 2020 Apr; 91():106337. PubMed ID: 32200189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Absence of ABL1 exon 2-encoded SH3 residues in BCR::ABL1 destabilizes the autoinhibited kinase conformation and confers resistance to asciminib.
    Leyte-Vidal A; DeFilippis R; Outhwaite IR; Kwan I; Lee JY; Leavitt C; Miller KB; Rea D; Rangwala AM; Lou K; Patel S; Alvarez A; Shokat KM; Bahar I; Seeliger MA; Shah NP
    Leukemia; 2024 Sep; 38(9):2046-2050. PubMed ID: 39085402
    [No Abstract]   [Full Text] [Related]  

  • 17. Mechanisms of resistance to the BCR-ABL1 allosteric inhibitor asciminib.
    Qiang W; Antelope O; Zabriskie MS; Pomicter AD; Vellore NA; Szankasi P; Rea D; Cayuela JM; Kelley TW; Deininger MW; O'Hare T
    Leukemia; 2017 Dec; 31(12):2844-2847. PubMed ID: 28819281
    [No Abstract]   [Full Text] [Related]  

  • 18. The e13a3 (b2a3) and e14a3 (b3a3) BCR::ABL1 isoforms are resistant to asciminib.
    Leske IB; Hantschel O
    Leukemia; 2024 Sep; 38(9):2041-2045. PubMed ID: 38879610
    [No Abstract]   [Full Text] [Related]  

  • 19. An evaluation of asciminib for patients with chronic myeloid leukemia previously treated with ≥2 tyrosine kinase inhibitors.
    García-Gutiérrez V; Hernandez-Boluda JC
    Expert Rev Hematol; 2022 Jun; 15(6):477-484. PubMed ID: 35583386
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of asciminib, a novel allosteric inhibitor of BCR-ABL1.
    Réa D; Hughes TP
    Crit Rev Oncol Hematol; 2022 Mar; 171():103580. PubMed ID: 35021069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.